Abstract
Adalimumab (ADA) (HUMIRA, Abbott®), a fully human IGG1 anti-TNFα monoclonal antibody, is indicated for induction and maintenance of remission in adult patients (pts) with moderate to severe Chron's disease (CD), regardless of previous experience with anti-TNFα therapy. There are only two case reports on its use and efficacy in paediatric CD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
